Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

This cohort study (n=379,033) found that compared to other non-SGLT2i antihyperglycaemics, use of empagliflozin was associated with a reduced risk of major adverse kidney events (eGFR decline >50%, end-stage kidney disease, or all-cause mortality; HR 0.68, 95% CI 0.64-0.73).


Diabetes Care